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Stroke
December 2015 (REVASCAT) , and Trial and Cost Effectiveness Evaluation of Intra-Arterial Thrombectomy in Acute Ischemic Stroke (THRACE). [3] [4] [5] [6] Patients enrolled in ESCAPE, EXTEND-IA, and SWIFT-PRIME showed a larger absolute treatment effect of IAT than those in MR CLEAN. One of the key differences of those trials compared with MR CLEAN was patient selection using advanced imaging. ESCAPE excluded patients with poor collateral circulation on CT angiography and low Alberta Stroke Program Early CT Score (ASPECTS) on CT, whereas EXTEND-IA included only patients with a small core and the presence of penumbra as detected on computed tomographic perfusion (CTP) imaging as did SWIFT-PRIME in a subset of patients.
CTP is thought to estimate areas of irreversible brain damage (ischemic core) and potentially salvageable areas with hypoperfusion (ischemic penumbra). 7, 8 Several studies support the concept of using CTP as a tool for clinical decision-making for patients with AIS for IAT. [9] [10] [11] [12] [13] However, its clinical value has not been established because of limitations in these studies, such as retrospective design, lack of controls, and small cohort sizes. The MR RESCUE trial was the first to investigate the value of perfusion imaging-based selection for IAT, but was hampered by small cohort size and the use of less effective stroke devices. 14 Hence, the value of CTP to predict functional outcome remains unclear. Moreover, the potential of CTP to differentiate between patients who will and will not benefit from IAT requires further study in a cohort that was not selected based on CTP.
The objective was to study the relationship between CTPderived parameters and functional outcome in patients with a proximal intracranial arterial occlusion enrolled in MR CLEAN. Furthermore, we investigated whether the efficacy of IAT on outcome was modified by the CTP-derived parameters by analyzing whether there was a significant interaction between CTP-derived parameters and treatment effect.
Methods
Patient Selection
Patients enrolled in MR CLEAN 2 for whom CTP source data were available were included in this study. MR CLEAN was a randomized trial investigating the effect of IAT versus best medical treatment, including intravenous alteplase, in patients with AIS. Patients were eligible for enrollment in MR CLEAN if they had a proximal intracranial arterial occlusion of the anterior circulation on vessel imaging. Permission of the Institutional Review Board and Ethics Committee was given, and patients or their legal representatives signed informed consent. A detailed description of the protocol and methods of MR CLEAN have been published previously. 15 Further exclusion criteria for the current substudy were CTP data with severe motion artifacts, insufficient intravascular contrast volume, incorrect timing of image acquisition after contrast injection, and truncation of the venous output or arterial input curves.
CTP Analysis
CTP analysis was performed by a trained observer (Dr Borst: stroke researcher with 2 years of experience in CTP analysis) as previously described 16 using Brain CT Perfusion software (Philips IntelliSpace, version 7.0, Brain CT Perfusion Package; Philips Healthcare, Best, The Netherlands). Philips Healthcare provided a workstation with CT Brain Perfusion software, but was not involved in the study design, study conduct, or preparation of the article. The default preprocessing steps included filtering, (3D) registration, and segmentation of brain tissue. Ischemic penumbra was defined as a relative mean transit time (MTT) 45% higher than that of the contralateral hemisphere (relative MTT >1.45) and a cerebral blood volume (CBV) >2.0 mL/100 g. Ischemic core was defined as a relative MTT >1.45 and a CBV <2.0 mL/100 g. 17 Time attenuation curves were classified as complete or truncated. 16 Volumes of ischemic core and penumbra were recorded, and the percentage ischemic core was calculated by dividing the ischemic-core volume by the total volume of hypoperfused tissue (ischemic-core volume plus penumbra volume) and multiplying by 100. We also determined whether patients satisfied the imaging mismatch criterion used in EXTEND-IA, defined as an ischemic core <70 mL and a penumbra of at least 10 mL and 20% larger than the ischemic core.
3,18
Statistical Analysis
Association of CTP-Derived Parameters With Functional Outcome and IAT Effect
Functional outcome assessed by the score on the modified Rankin Scale (mRS) at 90 days was the primary outcome measure. 19 The primary variables of interest were ischemic-core volume, penumbra volume, percentage ischemic core, and treatment allocation (IAT or usual care, including intravenous alteplase). The association of the CTP-derived parameters and treatment allocation with outcome was estimated with univariable and multivariable ordinal logistic regression as an (adjusted) odds ratio (OR) for a shift in the direction of a better outcome on the mRS. 20 To minimize the effect of outliers, the CTP-derived parameters were truncated at the 2.5 percentile and 97.5 percentile. 21 The ORs were adjusted by including the following baseline patient characteristics in the multivariable model: age, sex, diabetes mellitus, atrial fibrillation, time from onset to imaging, and stroke severity assessed by the National Institutes of Health Stroke Scale. The following imaging covariates were included: ASPECTS ≥7 on noncontrast CT and presence of internal carotid artery terminus occlusion as assessed on CTA. Details regarding data collection, imaging acquisition for noncontrast CT and CTA, and scoring by expert neuroradiologists were previously reported. 2 We investigated whether the efficacy of IAT on outcome was modified by the CTP-derived parameters by analyzing whether there was a significant interaction with treatment on functional outcome. The interaction was tested for each CTP-derived parameter in a multivariable ordinal logistic regression model, including the CTP-derived parameter of interest, treatment allocation, and the multiplicative interaction term between these variables. In addition, the interaction between the CTP-derived parameters and treatment effect was tested for the dichotomized end points mRS 0 to 2 and mRS 0 to 3.
Effect of CTP-Based Mismatch on Efficacy of IAT
In previous research, it has been suggested that CTP-derived mismatch may be useful for selection of patients for IAT. 3 To investigate the effect of CTP mismatch selection on the efficacy of IAT, the mRS scores and baseline characteristics were compared between patients with and without mismatch. Interaction between mismatch and treatment effect was tested on the full mRS and dichotomized end points mRS 0 to 2 and mRS 0 to 3. The relation between CTP-derived ischemic-core volume and 90-day mRS, stratified by the presence or absence of mismatch, was visualized by means of a scatterplot.
The mRS scores, mortality, and baseline characteristics of patients with a CTP-derived ischemic-core volume ≥70 and <70 mL were also compared. For patients with an ischemic core ≥70 mL, outcome (mRS 0-2 and mRS 0-3) was compared between patients who were allocated to IAT and patients who were allocated to usual care alone. All statistical analyses were performed with Stata/SE 13·1 (StataCorp, TX). underwent CTP imaging, no source image data were available. Thirty-five percent (94/269) of the patients were excluded because of motion (n=28), insufficient intravascular contrast (n=2), incorrectly timed start of acquisition (n=14), and truncation of the venous output curve or arterial input curve (n=50). The remaining data from 175 patients were used for further analysis.
Mean age was 61 years (range 23-93 years), and 53% (93/175) were men. The median time from onset to CTP imaging was 177 minutes (interquartile range [IQR]: 108-251 minutes). The median time from CTP imaging to randomization was 30 minutes (IQR: 18-53 minutes), and the median time from CTP imaging to IAT (groin puncture) was 84 minutes (IQR: 63-116 minutes). The median brain coverage of the CTP data was 60 mm (IQR: 40-100, range 28.8-160 mm), and the median acquisition time was 50 s (IQR: 48-60, range 45-60 s). The median core volume was 33 mL (IQR: 13-62, range 1.6-168 mL), median penumbra volume was 80 mL (IQR: 36-123, range 3.4-282 mL), and the median ischemic-core percentage was 28% (IQR: 18-45, range 3.3%-96%). Table 1 displays the baseline characteristics of the study cohort.
Association of CTP-Derived Parameters With Outcome and IAT Effect
CTP-derived ischemic-core volume (P<0.001) and percentage ischemic core (P=0.002) were associated with functional outcome (Table 2 ). Penumbra volume (P=0.41) was not associated with functional outcome. The adjusted OR for a shift toward better outcome on the mRS for ischemic core was 0.79 per 10 mL (95% confidence interval [CI]:0.71-0.89) and for percentage ischemic core was 0.82 per 10% (95% CI: 0.66-0.90). We observed no interaction between CTP-derived parameters (ischemic-core volume, penumbra volume, and percentage ischemic core) and treatment effect (P>0.80), indicating that the effect of IAT was independent of the CTP-derived parameters in our study cohort. Neither did we observe a significant interaction between the CTP-derived parameters and treatment effect on dichotomized end point mRS 0 to 2 (P>0.67) or mRS 0 to 3 (P>0.40). The association of the covariates with functional outcome is presented in Table I in the online-only Data Supplement.
Effect of CTP-Based Mismatch on Efficacy of IAT
Eighty-five percent of the patients (102/175) fulfilled the CTP mismatch criteria. Patients did not meet the CTP mismatch criteria as a result of the ischemic-core volume ≥70 mL (n=34) or penumbra-core volume <10 mL (n=21) or penumbra/ischemic-core ratio <1.2 (n=43). Figure I in the online-only Data Supplement shows the relation between CTP-derived ischemic-core volume and mRS, stratified by the presence or absence of mismatch (please see the online-only Data Supplement for figure and tables).
Except for National Institutes of Health Stroke Scale and presence of internal carotid artery terminus occlusion, the baseline characteristics of patients with and without mismatch were similar. (See Table II in the online-only Data Supplement for the baseline characteristics and CTP-derived volumes for patients with and without mismatch.) There was no significant interaction between mismatch and treatment effect on the full Figure 1 ). The mRS score of patients with an ischemic-core volume ≥70 (n=34) and <70 mL (n=141) is presented in Figure 2 . See Table III in the online-only Data Supplement for the baseline characteristics and CTP-derived volumes for patients with an ischemic core ≥70 and <70 mL. Overall, the mortality was higher in patients with an ischemic-core volume >70 mL as compared with those with a volume <70 mL, 35% (12/34) versus 9% (13/141), respectively (P<0.005). From Figure 2 , it can be concluded that there is a shift toward better outcome after IAT compared with usual care alone for both patient groups (ischemic-core volume: <70 mL and ≥70 mL). Eight percent (1/13) of the patients with an ischemic-core volume ≥70 mL allocated to IAT had a good outcome versus 0 (out of 21) patients allocated to usual care. The rate of a moderate outcome (mRS 0-3) was 46% (6/13) versus 10% (2/21) in favor of IAT in patients with an ischemic core ≥70 mL.
Discussion
This study shows that in our cohort of patients with AIS as a result of a proximal intracranial arterial occlusion, larger CTP ischemic-core volume is associated with worse functional outcome. Furthermore, we observed no significant interaction between treatment effect and CTP core volume, nor the other CTP-derived parameters in our study cohort. Although patients with a large CTP-derived ischemic core mostly had a poor functional outcome (mRS>2), we still observed a beneficial effect of IAT.
Because inclusion of patients was not based on CTP imaging in our trial, we were able to compare the effect of IAT between patients with and without a perfusion imaging-based mismatch. The MR CLEAN steering committee allowed local investigators to perform CTP if that was their standard of care, but requested that they would not take the CTP analysis into account in the decision to include a patient in the trial or not. Almost all CTPs were acquired before randomization. From a previous analysis of MR CLEAN, it was concluded that the availability of CTP had no influence on the selection of patients because we observed no difference in clinical outcome of patients who underwent CTP imaging and those who did not undergo CTP imaging. 22 In contrast to the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) trial, 14 in which no beneficial effect of IAT was observed regardless of mismatch, we observed a positive IAT effect in both patients with and without mismatch. Regardless of treatment allocation, we found that the percentage of patients with good outcome (mRS 0-2) was higher for patients with mismatch, which is in line with a previous study in which the percentage of intra-arterially treated patients with good outcome was higher for patients with mismatch 10 Consistent with a previous study that found that patients with a core volume ≥70 mL on magnetic resonance imaging are unlikely to have a good outcome (90-day mRS 0-2), 23 only 3% (1/34) of our patients with an ischemic-core volume ≥70 mL achieved a good outcome. Nevertheless, we observed a shift toward better functional outcome after IAT in patients with an ischemic-core volume ≥70 mL compared with after standard care alone. Indeed, the rate of a moderate outcome (mRS 0-3) was 46% (6/13) versus 10% (2/21) in favor of intervention in this cohort. These findings highlight the important difference between a prognostic biomarker and a biomarker that predicts treatment effect. CTP seems useful for predicting functional outcome, but cannot reliably identify patients who will not benefit from intra-arterial therapy and, therefore, should be excluded from treatment.
This study has several limitations, which are largely related to the drawbacks of perfusion imaging. Because MR CLEAN was a multicenter study, the imaging data were acquired with different scanners using different protocols. This resulted in heterogeneous CTP data with respect to acquisition time and brain coverage. 24 However, this is a reflection of CTP in the current clinical setting. To minimize the effect of heterogeneity, we also investigated the association of functional outcome with percentage CTP ischemic core, which should be less affected by differences in scan protocols. Furthermore, a large number of patients for whom source data were available were excluded from analysis in this CTP substudy because of severe motion artifact, insufficient intravascular contrast injection, incorrectly timed acquisition after contrast injection, and truncation of the venous output or arterial input curves. This high proportion of poor-quality CTP studies highlights the significant challenges of performing perfusion imaging in the acute clinical setting. 25 The use of delay-insensitive CTP software might have increased the accuracy of the CTP analysis. 26 However, similar results have been reported for delay-sensitive and delay-insensitive methods when the correct thresholds are applied. 27 The use of relative cerebral blood flow and T max to define ischemic core and penumbra, respectively, may improve the accuracy of CTP analysis. 28 This was, however, not possible with the software used in our study. Our results pertain to the use of Philips software and MTT and CBV to define ischemic core and penumbra. However, it should be further noted that in the study by Kamalian et al, the difference in discrimination of ischemic core between cerebral blood flow and CBV was on the order of 5%, which although statistically significant may not be clinically relevant. 28 The median acquisition time of the CTP data was 50 s. Such short acquisition times may cause truncation of the tissue time attenuation curves, which results in overestimation of the ischemic-core volumes. 16 Nevertheless, the MTT and CBV thresholds used to determine ischemic core and penumbra in this study were derived from CTP data with similarly short acquisition times. 17 The confidence intervals of the interaction terms between CTP-derived variables and treatment effect are wide, thus limiting the generalizability of our observation regarding the absence of significant effect modification. Given that CTP was not obligatory for inclusion in MR CLEAN, this study is composed of a subset of the complete trial cohort, and therefore, the lack of significant interaction could be caused by the limited number of patients included in this study.
In conclusion, this study demonstrates that larger baseline CTP-derived ischemic-core volume is associated with worse functional outcome in patients with AIS because of proximal intracranial occlusion of the anterior circulation. CTP was not able to identify patients who will have no benefit from IAT because we observed no significant interaction between treatment effect and CTP core volume in our study cohort. Although no definite conclusion could be drawn, our study does not support the use of CTP-based selection of patients with AIS otherwise eligible for IAT.
SUPPLEMENT MATERIAL Figure I . The relationship between CTP-derived ischemic core volume and mRS at 90 days. Mismatch is defined as an ischemic core < 70 ml and a penumbra of at least 10 ml and 20% larger than the ischemic core. IAT: intra-arterial treatment. 
